Kurzfassung

This analysis will use biomaterial as well clinical data of the conducted and completed AIO/EORTC POWER (40101) Study. The outcome of these analyses will support the group’s strategy in form of a deeper knowledge of immunogenic factors and expression profiles of ESCC patients in the palliative setting. In an additional step, we will merge these results with results of the combined ESCC analysis performed by our collaboration group from ESCC treated with anti-EGFR (aEGFR) plus trimodal setting...This analysis will use biomaterial as well clinical data of the conducted and completed AIO/EORTC POWER (40101) Study. The outcome of these analyses will support the group’s strategy in form of a deeper knowledge of immunogenic factors and expression profiles of ESCC patients in the palliative setting. In an additional step, we will merge these results with results of the combined ESCC analysis performed by our collaboration group from ESCC treated with anti-EGFR (aEGFR) plus trimodal setting (Leopard-1, Leopard-2, SAKK75-08 and ESCC study from Baruch Brenner). This will lead to an extended overview for immunogenic factors and the cellular configuration supporting a new trial strategy with immune oncological (IO) combinations (either IO-IO or IO-plus aEGFR, or IO-aEGFR plus Chemotherapy). This could support the development of new EORTC study proposal(s) in the ESCC indication, which is yet to be addressed in the group’s portfolio.» weiterlesen» einklappen